Noble Financial Issues Negative Outlook for CVKD Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Analysts at Noble Financial reduced their Q1 2026 EPS estimates for Cadrenal Therapeutics in a note issued to investors on Wednesday, April 1st. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings of ($1.86) per share for the quarter, down from their previous estimate of ($1.33). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. Noble Financial also issued estimates for Cadrenal Therapeutics’ Q2 2026 earnings at ($1.95) EPS, Q3 2026 earnings at ($2.10) EPS, Q4 2026 earnings at ($1.85) EPS and FY2026 earnings at ($7.74) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.24).

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $32.00.

Cadrenal Therapeutics Price Performance

Cadrenal Therapeutics stock opened at $4.70 on Friday. The stock has a 50-day moving average price of $6.63 and a 200 day moving average price of $9.37. The company has a market capitalization of $11.78 million, a price-to-earnings ratio of -0.70 and a beta of 1.53. Cadrenal Therapeutics has a 52 week low of $4.21 and a 52 week high of $17.97.

Hedge Funds Weigh In On Cadrenal Therapeutics

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in Cadrenal Therapeutics by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after buying an additional 1,818 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in Cadrenal Therapeutics in the third quarter valued at $103,000. DRW Securities LLC acquired a new position in shares of Cadrenal Therapeutics in the fourth quarter worth about $171,000. Finally, Citadel Advisors LLC acquired a new position in shares of Cadrenal Therapeutics in the third quarter worth about $274,000. 7.92% of the stock is owned by hedge funds and other institutional investors.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.